Calls grow for British government to speak out against Hong Kong’s media crackdown

British lawmakers and the son of jailed media magnate Jimmy Lai have criticized the United Kingdom for failing to oppose China’s crackdown on Hong Kong’s once-free media and support embattled journalists in the city. 

“The British government did not really call for the release of my father,” Lai’s son Sebastien told journalists as the All Party Parliamentary Group on Hong Kong published a report on the state of the city’s media amid an ongoing crackdown under a draconian security law imposed by Beijing.

“This is a man who has stood up for Hong Kong’s freedoms for the past few decades, and a publisher who has stood up for his beliefs like the rule of law, free speech, democracy, and who has gone straight to jail for it,” he said.

Lai, whose Next Digital media empire and its flagship Apple Daily newspaper were forced to close amid a national security investigation in 2021, will be tried for “collusion with a foreign power” and other charges linked to “seditious publications.”

The parliamentary group’s report calls on the British government to issue emergency visas to journalists at risk of arrest or prosecution in Hong Kong, and to apply targeted sanctions to individuals responsible for Lai’s arrest and arbitrary detention.

“[The government should] call upon Hong Kong authorities to restore full editorial independence and end censorship campaigns at the territory’s public broadcaster Radio Television Hong Kong and others [and] provide assistance to journalists targeted in Hong Kong, including by providing them with emergency visas,” it said.

It said the British government should “treat the case of Jimmy Lai, a British citizen and political prisoner, as a political priority.”

“This includes applying pressure for his release, and deeming his current arrest as arbitrary detention,” the report said.

‘Kafkaesque’

It slammed “Kafkaesque” judicial arrangements under the national security law imposed by the Communist Party from July 1, 2020.

“The handling of the cases against Jimmy Lai, and the concerns raised regarding due process and the rule of law, show how the Kafkaesque process does not leave any sense that he could possibly have a fair trial in Hong Kong,” the report said, blaming the national security law for “crush[ing] freedom of expression and media pluralism in Hong Kong.”

British barrister Caoilfhionn Gallagher, who heads Lai’s international legal team, said she and her colleagues have been targeted by pro-China abuse online, which has included threats of rape, dismemberment and death, but that the British government has said nothing on the matter.

Hong Kong journalist Lam Yin-bong, former assignment editor at Stand News, which shut down under investigation by national security police a few months after the Apple Daily was forced to close, said he is struggling to make ends meet through his one-man news operation ReNews.

ENG_CHN_HongKongMedia_04262023.2.jpg
British barrister Caoilfhionn Gallagher says she and her colleagues have been targeted by pro-China abuse online, which has included threats of rape, dismemberment and death. Credit: Lu Xi

“It’s hard for small or independent media in Hong Kong to get in touch with foreign governments and organizations, let alone get direct funding, which could lead to charges of ‘collusion with foreign forces’ [under the national security law],” Lam said.

“Any financial transactions between non-government organizations and anyone overseas can now be used as evidence of a crime,” he said.

Retraining exiled journalists

Hong Kong journalists who fled the city amid an ongoing crackdown on public dissent and political opposition have vowed to keep campaigning for press freedom for the city from overseas, as well as retraining exiled journalists for jobs elsewhere.

Former Apple Daily reporter Shirley Leung, who has moved to the democratic island of Taiwan to set up the Hong Kong-focused Photon News, said it has been very hard for journalists to do their jobs in Hong Kong since the crackdown began in the wake of the 2019 protest movement.

“The pervasive sense of fear [in Hong Kong] makes it seem very hard to report freely, or to fully report everything interviewees are saying,” Leung said. “To be honest, I was censoring myself.”

“Since I left Hong Kong, I have enjoyed a lot more freedom of speech and of the press, so we are now all trying to figure out how to make this work,” she said, using a Chinese saying “crossing the river by feeling the stones.”

The United Nations Special Rapporteur on the independence of judges and lawyers, Margaret Satterthwaite, wrote to the Chinese government last week saying that the national security law had interfered with the rule of law in Hong Kong.

“The [law] could undermine the independence of the judiciary and remove procedural safeguards essential for a fair trial, Satterthwaite wrote in a summary of her letter on her Twitter account.

She said the law gives the executive new powers, including the power to decide which judges are eligible to hear national security cases, to authorize some trials to proceed without a jury, and to transfer certain cases to be heard in mainland China, while restricting judicial review by vesting the power to interpret the law in the Standing Committee of the National People’s Congress in Beijing.

Meanwhile, the law has also expanded police powers, allowing officers to conduct searches and surveillance without a warrant, she said.

Recent moves to disqualify Jimmy Lai’s British barrister Tim Owen from representing him at his national security trial will likely soon lead to an outright ban on foreign lawyers working on national security cases, she wrote.

“I recommend review and reconsideration of the National Security Law to ensure that the law is in compliance with China’s international human rights obligations with respect to the HKSAR,” Satterthwaite wrote.

Translated by Luisetta Mudie. Edited by Malcolm Foster.

Modelo and Juixxe Team Up to Celebrate Street Vendors for the Launch of Modelo Spiked Aguas Frescas

The No. 1 imported Mexican beer brand and famous Southern California changemaker, Juixxe, recognize the Fighting Spirit of aguas frescas vendors, who keep the beloved Mexican street drink tradition alive

CHICAGO, April 27, 2023 (GLOBE NEWSWIRE) — Modelo announced today the launch of its latest product innovation – Modelo Spiked Aguas Frescas – a new line of vibrant and flavorful spiked malt beverages that celebrate the bold, fruit-forward taste of authentic aguas frescas found in Mexican street markets, with a twist. The brand partnered with Jesus Morales aka Juixxe, a changemaker known for gifting hundreds of thousands of dollars to street vendors who struggled during the pandemic, to honor the roots of its new product. Furthering his commitment to being a force for good, Modelo and Juixxe bought out hard working, Southern California-based street vendors’ carts earlier this month. Modelo flew and hosted the merchants in Las Vegas to be among the first to try the new beverage – that they helped inspire – at the Modelo Spiked Aguas Frescas launch celebration.

“Honoring the brand’s authentic Mexican heritage sets Modelo apart and we know that without the tireless fighting spirit of street vendors, aguas frescas would not be the staple in Hispanic communities that they are today,” said Greg Gallagher, Vice President of Brand Marketing, Modelo. “Through our partnership with Juixxe, Modelo Spiked Aguas Frescas recognizes and celebrates street vendors for perfecting the beloved flavors and taste experience that inspired our new brand.”

“Growing up, I would see a street vendor and always ask my parents to buy me papitas or a refreshing aguas frescas and I made it my mission to give back to street vendors in ways that spotlight the important role they play in our communities,” said Juixxe. “Partnering with Modelo Spiked Aguas Frescas helped me elevate our appreciation of street vendors’ tenacity and hard work and they were the perfect guests to celebrate with at the Modelo Spiked Aguas Frescas launch party in Las Vegas.”

Modelo Spiked Aguas Frescas is currently available in Las Vegas in four varieties:

  • Modelo Spiked Aguas Frescas Piña (Pineapple) is an aromatic, juicy pineapple flavor with a balanced sweetness for sessionability.
  • Modelo Spiked Aguas Frescas Flor de Jamaica (Hibiscus) is a sweet, floral flavor that contains fruit notes with a slight tartness.
  • Modelo Spiked Aguas Frescas Sandía (Watermelon) is a refreshing flavor that has a sweet and indulgent watermelon juice taste and aroma.
  • Modelo Spiked Aguas Frescas Pepino y Limón (Cucumber-Lime) is a crisp flavor that combines notes of cucumber with sweet and zesty lime.

All varieties are 171-197 calories, 4.5% ABV, have <0.5% carbonation, resulting in a smooth and non-carbonated taste experience, and contain 20-25 grams of sugar*.

For more on Juixxe and Modelo Spiked Aguas Frescas’ partnership, visit Youtube. For more information on Modelo Spiked Aguas Frescas and other Casa Modelo products, visit www.modelousa.com.

* Per 12 fl. oz. serving of average analysis: 4.5% ABV, Calories 193, Carbs 26.4 grams, Protein 0.2 grams, Fat 0 grams (Piña); 4.5% ABV, Calories 197, Carbs 34.2 grams, Protein 0.2 grams, Fat 0 grams (Sandía); 4.5% ABV, Calories 189, Carbs 25.7 grams, Protein 0.2 grams, Fat 0 grams (Pepino y Limón); 4.5% ABV, Calories 171, Carbs 22.6 grams, Protein 0.3 grams, Fat 0 grams (Flor de Jamaica).

ABOUT MODELO® 
Born in 1925 in the small town of Tacuba, Mexico, Modelo has been bringing distinctive high-quality beer to those with the Fighting Spirit ever since, including Modelo Especial®, Modelo Negra®, Modelo Chelada Especial™, and a flavorful lineup of Modelo Cheladas™. Modelo Especial is a golden, full-flavored Pilsner-style lager with a clean, crisp finish. As the #1 imported beer in the U.S., Modelo Especial recently surpassed 175MM cases sold in 2022 and became the #2 beer brand in the category. The Modelo family of beers are exclusively brewed in Mexico and imported and marketed for the U.S. by Constellations Brands.

Media Contact:
Stephanie McGuane
Stephanie.mcguane@cbrands.com

GlobeNewswire Distribution ID 8826698

MODIFI Expands Its Footprint to Singapore to Better Serve Business Customers in Asia

MODIFI Expands Its Footprint to Singapore

MODIFI Expands Its Footprint to Singapore to Better Serve Business Customers in Asia

SINGAPORE, April 27, 2023 (GLOBE NEWSWIRE) — MODIFI, a leading European fintech company specializing in cross-border payment solutions and provision of liquidity for exporters around the world, announces the opening of its new office in Singapore. The expansion is part of MODIFI’s strategy to strengthen its global presence and better serve customers in Asia.

The company’s Chief Commercial Officer, Matthias Hendrichs, will relocate from Germany to Singapore to lead the new office and oversee the company’s growth in the region. Hendrichs brings over 16 years of experience in Asia and has played an instrumental role in driving MODIFI’s global expansion to date.

“We are thrilled to announce the opening of our new office in Singapore, which marks an important milestone in our journey to expand our global footprint,” said Nelson Holzner, CEO of MODIFI. “With this new office, we aim to deepen our relationships with customers in Asia and provide them with the best cross-border payment solutions available.”

Singapore’s strategic location at the intersection of major shipping routes has made it a crucial port of call for ships traveling between Europe, Asia, and the Middle East. Moreover, with a well-developed air transport network and Changi Airport serving as a major hub for international flights, Singapore is an efficient location for businesses to transport goods and connect with global markets. Additionally, Singapore has recently surpassed Hong Kong and now ranks as the third largest financial center in the world.

MODIFI’s expansion to Singapore comes at a time when the company is experiencing rapid growth and increasing demand for its services in Asia. The company’s innovative platform offers exporters the No 1 payment method in cross-border business: With MODIFI, exporters get paid instantly while buyers can pay up to 180 days later. MODIFI’s solutions have already helped over 1,500 businesses around the world grow their business and expand into new markets.

“We are excited to be part of Singapore’s vibrant fintech ecosystem and collaborate with local partners to provide our customers with the best service,” said Hendrichs. “Our goal is to help businesses in Asia thrive by providing them with the support they need to succeed in today’s global marketplace.”

MODIFI’s new office is in Singapore’s financial district and will serve as the company’s regional headquarters for Asia.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/13e859a3-c59b-4abd-aca2-7fa61b2e475e

Contact person:

Sara Debevec, PR manager, marketing@modifi.com

GlobeNewswire Distribution ID 1000806529

Junta raids force more than 7,000 villagers to flee Salingyi

More than 7,000 residents of villages in Sagaing region’s Salingyi township have fled their homes ahead of junta raids, according to a member of the pro-democracy Salingyi-Yinmarbin Strike Committee.

The man, who didn’t wish to be named, said a column of 150 troops descended on the township on Thursday morning, leading residents of nine villages to flee.

“Residents from those villages are still on the run,” he said. “There have been no arrests.”

He said that the column of troops was made up of soldiers based in Salingyi town and others from a Chinese-owned copper project in the township.

The Strike Committee member said troops had killed five civilians who they had brought with them from other villages. He didn’t know the names of the dead.

signal-2023-04-27-14-43-45-758-1.jpg
Residents of Salingyi township, Sagaing region, crown into a truck as they flee ahead of junta raids on April 27, 2023. Credit: Facebook: Ah Nyar Pyit Taing Htaung Lay Myar Group 

The military has intensified an already bloody campaign in Sagaing region this year, declaring martial law in 11 townships in February to try to wrest control of them from People’s Defense Forces and defend foreign-owned mining interests.

This month alone, troops have torched hundreds of homes in Sagaing region, and killed around 200 civilians in the bombing of Pa Zi Gyi village.

There were more than 1.8 million internally displaced persons across Myanmar as of April 10, 2023, according to the UN Office for the Coordination of Humanitarian Affairs.

Nearly 1.5 million of them fled their homes due to fighting since the Feb. 1, 2021 coup.

Translated by RFA Burmese. Edited by Mike Firn.

Iveco Group N.V. to present its 2023 First Quarter Results on 11th May 2023

Turin, 27th April 2023. Iveco Group N.V. (MI: IVG) confirmed today that its financial results for the First Quarter of 2023 will be presented on Thursday, 11th May 2023.

A live audio webcast of the conference call will begin at 11:00am CEST / 10:00am BST on Thursday, 11th May 2023.

Details for accessing the webcast are available at the following link:

Q1 2023 Iveco Group webcast

The related press release and presentation material will be posted on the corporate website at www.ivecogroup.com on Thursday, 11th May 2023.

For those unable to take part in the live session, a replay will be available in the Investors section of the company website (www.ivecogroup.com) following the conference call.

Iveco Group N.V. (MI: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain technologies in the agriculture, construction, marine, power generation, and commercial vehicles sectors; IVECO BUS and HEULIEZ, mass-transit and premium bus and coach brands; IDV, for highly-specialised defence and civil protection equipment; ASTRA, a leader in large-scale heavy-duty quarry and construction vehicles; MAGIRUS, the industry-reputed firefighting vehicle and equipment manufacturer; and IVECO CAPITAL, the financing arm which supports them all. Iveco Group employs more than 35,000 people around the world and has 26 manufacturing plants and 29 R&D centres. Further information is available on the Company’s website www.ivecogroup.com

Media Contacts:
Francesco Polsinelli, Mob: +39 335 1776091
Fabio Lepore, Mob: +39 335 7469007
E-mail: mediarelations@ivecogroup.com

Investor Relations:
Federico Donati, Tel: +39 011 0073539
E-mail: investor.relations@ivecogroup.com

Attachment

GlobeNewswire Distribution ID 1000806528

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

SHANGHAI, China, April 27, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the pre-specified interim analysis of the RENOTORCH study (NCT04394975) has been completed. RENOTORCH is a multi-center, randomized, open-label, active-controlled phase 3 clinical study evaluating toripalimab in combination with axitinib for the first-line treatment of patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma (“RCC”). The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of progression free survival (“PFS”, based on independent radiographic review) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental new drug application in the near future.

Globally, renal carcinoma is the third most common type of malignancy in the urinary system, and RCC accounts for 80%-90% of all cases. According to data published in the Chinese Medical Journal, in 2022, there were approximately 77,000 new cases of renal carcinoma and 46,000 deaths due to this disease in China. About one-third of the renal cell carcinoma patients had distant metastasis at initial diagnosis, while 20%-50% of the patients with localized tumors developed distant metastasis after nephrectomy. According to the risk classification of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), the median overall survival (“OS”) of patients with low, medium and high risk metastatic RCC receiving anti-vascular targeted treatment was 35.3, 16.6 and 5.4 months, respectively. Therefore, the need for new treatment options is more urgent for patients with medium and high risk advanced RCC compared to low-risk patients.

In recent years, PD-(L)1 inhibitors combined with anti-vascular targeted drugs have achieved success in the first-line treatment of advanced RCC in many countries around the world, replacing anti-vascular targeted drug monotherapy as the new standard. Compared to anti-vascular targeted drug monotherapy, the combination of PD-(L)1 monoclonal antibody and anti-vascular targeted drugs has demonstrated significant improvements in patients’ PFS, objective response rate (“ORR”), and OS. However, no therapy combining PD-(L)1 therapy with anti-vascular targeted drugs for the first-line treatment of advanced RCC has been approved in China.

As the first pivotal phase 3 study of immunotherapy for patients with advanced RCC in China, RENOTORCH is a multi-center, randomized, open-label, active-controlled study aiming to evaluate the efficacy and safety of toripalimab in combination with axitinib versus sunitinib monotherapy for the first-line treatment of patients with intermediate to high-risk unresectable or metastatic RCC. Based on the interim analysis of the study, toripalimab in combination with axitinib for the first-line treatment of patients with advanced RCC significantly reduced the risk of disease progression or death compared to sunitinib monotherapy, while improving secondary endpoints such as ORR. The safety profile of toripalimab in the study was consistent with known risks, and no new safety signals were identified. Further details on the study data will be presented at an upcoming international academic conference.

“Thanks to the collective efforts of the investigators, patients, R&D teams and many others, the RENOTORCH study has been a great success,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences. “This study represents a crucial milestone for our company as an innovative Chinese pharmaceutical company that aims to address the nation’s unmet medical needs. We believe that RENOTORCH’s positive results will help bridge the gap in renal cancer PD-(L)1 immunotherapy in China, and we will take all the necessary steps to commercialize this achievement and provide new and effective combination immunotherapy options for domestic patients.”

About RENOTORCH

The RENOTORCH study is a multi-center, randomized, open-label, active-controlled phase 3 study aiming to evaluate the efficacy and safety of toripalimab in combination with axitinib versus sunitinib monotherapy for the first-line treatment of patients with intermediate to high-risk unresectable or metastatic RCC. Enrolled individuals were randomly assigned in a 1:1 ratio to receive toripalimab in combination with either axitinib or sunitinib until disease progression or intolerable toxicity. The primary endpoint is PFS as assessed by the Independent Radiographic Review Committee (“IRC”), and secondary endpoints include PFS as assessed by investigators, ORR as assessed by IRC or investigators, duration of response (DOR) and disease control rate (DCR), OS, safety profile and etc. The study is jointly led by principal investigators Professor Jun GUO of the Peking University Cancer Hospital and Professor Yiran HUANG of Renji Hospital of Shanghai Jiao Tong University School of Medicine. The study was launched in August 2020, with 47 domestic centers participating and a total of 421 patients enrolled and randomized.

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

 GlobeNewswire Distribution ID 8826915